Related Experiment Video

Updated: May 12, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Anticoagulation for non-valvular atrial fibrillation: new anticoagulant agents

Alper Kepez1, Okan Erdoğan

  • 1Department of Cardiology, Faculty of Medicine, Marmara University, İstanbul-Turkey.

Anadolu Kardiyoloji Dergisi : AKD = the Anatolian Journal of Cardiology
|April 18, 2013
PubMed

Insights

New oral anticoagulants like dabigatran and rivaroxaban offer alternatives to warfarin for preventing stroke in atrial fibrillation (AF) patients. These novel drugs provide predictable effects without routine monitoring, addressing limitations of traditional therapies.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Atrial fibrillation (AF) is a prevalent cardiac arrhythmia linked to systemic thromboembolism.
  • Vitamin K antagonists (VKAs) like warfarin were the primary oral anticoagulants for AF stroke prevention.
  • VKA limitations, including the need for monitoring, spurred the development of novel anticoagulants.

Purpose of the Study:

  • To review the pharmacodynamic and pharmacokinetic profiles of new oral anticoagulants.
  • To overview clinical trial results for novel anticoagulants in AF.
  • To discuss current controversies surrounding the clinical use of these new drugs.

Main Methods:

  • Review of pharmacodynamic and pharmacokinetic data for novel oral anticoagulants.
  • Analysis of large-scale phase III clinical trial outcomes.
  • Synthesis of current literature and expert opinions on clinical application.

Main Results:

  • Dabigatran and rivaroxaban are FDA-approved for preventing systemic embolism in non-valvular AF.
  • These novel agents offer predictable pharmacokinetic profiles, reducing the need for coagulation monitoring.
  • Clinical trials demonstrate efficacy and safety, though controversies regarding their application persist.

Conclusions:

  • Novel oral anticoagulants represent a significant advancement in AF management.
  • These drugs offer advantages over VKAs, particularly in terms of convenience and predictability.
  • Ongoing evaluation and discussion are crucial for optimizing the clinical use of these therapies.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Robotic Ablation of Atrial Fibrillation11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...